Gossamer Bio Key Executives
This section highlights Gossamer Bio's key executives, including their titles and compensation details.
Find Contacts at Gossamer Bio
(Showing 0 of )
Gossamer Bio Earnings
This section highlights Gossamer Bio's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
$1.08
Stock Price
$245.40M
Market Cap
144
Employees
San Diego, CA
Location
Financial Statements
Access annual & quarterly financial statements for Gossamer Bio, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $114.70M | $- | $- | $- | $- |
| Cost of Revenue | $- | $4.38M | $4.43M | $5.17M | $4.27M |
| Gross Profit | $114.70M | $-4.38M | $-4.43M | $-5.17M | $-4.27M |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $138.49M | $145.30M | $170.92M | $170.27M | $160.85M |
| General and Administrative Expenses | $36.13M | $38.45M | $47.61M | $45.78M | $49.73M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $36.13M | $38.45M | $47.61M | $45.78M | $49.73M |
| Other Expenses | $- | $- | $1.51M | $799.00K | $-174.00K |
| Operating Expenses | $174.62M | $183.76M | $218.53M | $216.05M | $210.58M |
| Cost and Expenses | $174.62M | $183.76M | $218.53M | $216.05M | $210.58M |
| Interest Income | $1.78M | $2.00M | $1.58M | $761.00K | $3.44M |
| Interest Expense | $11.52M | $13.51M | $13.88M | $19.44M | $12.67M |
| Depreciation and Amortization | $4.15M | $1.61M | $4.43M | $5.17M | $4.27M |
| EBITDA | $-39.97M | $-172.15M | $-211.07M | $-209.32M | $-233.96M |
| EBITDA Ratio | -34.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-59.92M | $-183.76M | $-218.59M | $-216.12M | $-233.96M |
| Operating Income Ratio | -52.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $4.28M | $3.94M | $-10.79M | $-17.88M | $-9.40M |
| Income Before Tax | $-55.63M | $-179.82M | $-229.38M | $-234.00M | $-243.36M |
| Income Before Tax Ratio | -48.50% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $893.00K | $- | $10.85M | $15.07M | $8.22M |
| Net Income | $-56.53M | $-179.82M | $-240.23M | $-249.08M | $-251.58M |
| Net Income Ratio | -49.28% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.25 | $-1.18 | $-2.84 | $-3.33 | $-3.67 |
| EPS Diluted | $-0.25 | $-1.18 | $-2.84 | $-3.33 | $-3.67 |
| Weighted Average Shares Outstanding | 226.23M | 152.62M | 84.57M | 74.84M | 68.51M |
| Weighted Average Shares Outstanding Diluted | 226.23M | 152.62M | 84.57M | 74.84M | 68.51M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.38M | $9.48M | $95.84M | $- | $6.78M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $992.00K | $986.00K | $1.01M | $1.10M | $1.15M | $- | $1.12M | $1.11M | $1.10M | $1.10M | $1.28M | $1.31M | $1.30M | $1.27M | $- | $- | $- | $- |
| Gross Profit | $9.38M | $9.48M | $94.85M | $-986.00K | $5.78M | $-1.10M | $-1.15M | $- | $-1.12M | $-1.11M | $-1.10M | $-1.10M | $-1.28M | $-1.31M | $-1.30M | $-1.27M | $- | $- | $- | $- |
| Gross Profit Ratio | 100.00% | 100.00% | 99.00% | 0.00% | 85.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $36.11M | $34.90M | $34.84M | $32.39M | $29.68M | $31.20M | $36.31M | $37.80M | $41.51M | $44.51M | $42.58M | $42.32M | $40.93M | $43.19M | $44.32M | $41.83M | $38.91M | $41.85M | $38.68M | $41.41M |
| General and Administrative Expenses | $9.39M | $8.50M | $8.67M | $9.57M | $9.06M | $9.29M | $9.98M | $10.13M | $12.83M | $11.50M | $11.28M | $12.00M | $10.71M | $12.46M | $11.26M | $11.35M | $15.88M | $11.45M | $11.65M | $10.75M |
| Selling and Marketing Expenses | $- | $- | $-742.00K | $- | $-714.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $9.39M | $8.50M | $7.93M | $9.57M | $8.34M | $9.29M | $9.98M | $10.13M | $12.83M | $11.50M | $11.28M | $12.00M | $10.71M | $12.46M | $11.26M | $11.35M | $15.88M | $11.45M | $11.65M | $10.75M |
| Other Expenses | $- | $- | $2.75M | $2.82M | $3.81M | $3.42M | $6.54M | $15.00K | $1.46M | $-332.00K | $587.00K | $-199.00K | $78.00K | $115.00K | $457.00K | $149.00K | $-130.00K | $-4.24M | $-1.53M | $893.00K |
| Operating Expenses | $45.51M | $43.40M | $42.76M | $41.96M | $38.02M | $40.49M | $46.28M | $47.94M | $54.34M | $56.01M | $53.86M | $54.32M | $51.65M | $55.65M | $55.58M | $53.17M | $54.79M | $53.29M | $50.34M | $52.16M |
| Cost and Expenses | $45.51M | $43.40M | $43.76M | $41.96M | $39.03M | $40.49M | $46.28M | $47.94M | $54.34M | $56.01M | $53.86M | $54.32M | $51.65M | $55.65M | $55.58M | $53.17M | $54.79M | $53.29M | $50.34M | $52.16M |
| Interest Income | $-744.00K | $430.00K | $1.75M | $344.00K | $310.00K | $405.00K | $695.00K | $587.00K | $594.00K | $465.00K | $300.00K | $224.00K | $236.00K | $191.00K | $141.00K | $193.00K | $366.00K | $- | $- | $- |
| Interest Expense | $2.74M | $2.73M | $2.92M | $3.13M | $3.24M | $3.34M | $3.43M | $3.50M | $3.46M | $3.48M | $3.48M | $3.47M | $4.94M | $4.89M | $4.83M | $4.78M | $4.75M | $- | $- | $- |
| Depreciation and Amortization | $1.07M | $1.10M | $992.00K | $986.00K | $1.01M | $1.10M | $1.15M | $1.14M | $1.12M | $1.11M | $1.10M | $1.10M | $1.28M | $1.31M | $1.30M | $1.27M | $1.21M | $1.18M | $987.00K | $895.00K |
| EBITDA | $-31.63M | $-28.10M | $53.08M | $-37.81M | $-43.90M | $-35.56M | $-37.92M | $-44.52M | $-51.18M | $-54.78M | $-51.89M | $-53.22M | $-50.06M | $-54.04M | $-53.70M | $-51.59M | $-54.55M | $-51.92M | $-65.34M | $-53.18M |
| EBITDA Ratio | -337.20% | -296.45% | 55.38% | 0.00% | -560.45% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-36.13M | $-33.92M | $52.09M | $-41.96M | $-39.03M | $-40.49M | $-46.30M | $-47.94M | $-54.36M | $-56.02M | $-53.87M | $-54.34M | $-51.66M | $-55.66M | $-55.60M | $-53.20M | $-60.09M | $-53.57M | $-65.34M | $-54.97M |
| Operating Income Ratio | -385.20% | -357.80% | 54.35% | 0.00% | -575.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $689.00K | $1.98M | $1.58M | $31.00K | $879.00K | $482.00K | $3.80M | $-1.22M | $-1.41M | $-3.34M | $-2.59M | $-3.44M | $-4.62M | $-4.58M | $-4.24M | $-4.44M | $-4.52M | $-4.24M | $-1.53M | $893.00K |
| Income Before Tax | $-35.44M | $-31.93M | $53.67M | $-41.93M | $-48.15M | $-40.01M | $-42.50M | $-49.16M | $-55.76M | $-59.36M | $-56.47M | $-57.78M | $-56.28M | $-60.25M | $-59.83M | $-57.64M | $-64.60M | $-57.81M | $-66.87M | $-54.07M |
| Income Before Tax Ratio | -377.85% | -336.87% | 56.00% | 0.00% | -709.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-2.41M | $-1.13M | $4.43M | $-986.00K | $-21.45M | $6.76M | $9.97M | $- | $1.42M | $3.34M | $2.59M | $3.44M | $-19.44M | $5.00M | $5.29M | $4.93M | $3.41M | $-902.00K | $15.00M | $2.81M |
| Net Income | $-33.03M | $-30.80M | $49.23M | $-41.93M | $-48.15M | $-40.01M | $-42.50M | $-49.16M | $-57.19M | $-62.70M | $-59.06M | $-61.23M | $-56.28M | $-60.25M | $-59.83M | $-57.64M | $-64.60M | $-57.81M | $-66.87M | $-54.07M |
| Net Income Ratio | -352.16% | -324.93% | 51.37% | 0.00% | -709.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.15 | $-0.14 | $0.22 | $-0.19 | $-0.21 | $-0.21 | $-0.45 | $-0.52 | $-0.61 | $-0.69 | $-0.77 | $-0.81 | $-0.74 | $-0.80 | $-0.80 | $-0.78 | $-0.88 | $-0.80 | $-1.00 | $-0.87 |
| EPS Diluted | $-0.15 | $-0.14 | $0.21 | $-0.19 | $-0.21 | $-0.21 | $-0.45 | $-0.52 | $-0.61 | $-0.69 | $-0.77 | $-0.81 | $-0.74 | $-0.80 | $-0.80 | $-0.78 | $-0.88 | $-0.80 | $-1.00 | $-0.87 |
| Weighted Average Shares Outstanding | 226.23M | 226.35M | 226.22M | 225.74M | 225.41M | 192.88M | 95.45M | 94.55M | 94.28M | 91.18M | 76.67M | 75.89M | 75.59M | 75.00M | 74.67M | 74.09M | 73.21M | 72.25M | 66.60M | 61.89M |
| Weighted Average Shares Outstanding Diluted | 226.23M | 226.35M | 238.54M | 225.74M | 225.41M | 192.88M | 95.45M | 94.87M | 94.28M | 91.18M | 76.67M | 75.89M | 75.59M | 75.00M | 74.67M | 74.09M | 73.21M | 72.25M | 66.60M | 61.89M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $46.07M | $32.11M | $111.97M | $183.40M | $486.06M |
| Short Term Investments | $248.44M | $264.32M | $143.71M | $141.81M | $26.57M |
| Cash and Short Term Investments | $294.52M | $296.43M | $255.68M | $325.22M | $512.63M |
| Net Receivables | $5.34M | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $-136.00K | $365.00K |
| Other Current Assets | $10.03M | $10.09M | $12.40M | $6.56M | $9.69M |
| Total Current Assets | $309.89M | $306.52M | $261.88M | $331.78M | $522.32M |
| Property Plant Equipment Net | $5.12M | $4.78M | $9.89M | $10.80M | $16.08M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $283.00K | $618.00K | $680.00K | $1.08M | $1.03M |
| Total Non-Current Assets | $5.40M | $5.40M | $10.57M | $11.88M | $17.11M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $315.29M | $311.92M | $272.45M | $343.66M | $539.43M |
| Account Payables | $2.32M | $5.53M | $1.46M | $3.24M | $7.51M |
| Short Term Debt | $961.00K | $14.91M | $14.60M | $2.90M | $3.63M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $41.73M | $31.16M | $33.17M | $33.71M | $27.51M |
| Total Current Liabilities | $45.01M | $51.60M | $49.23M | $39.86M | $38.65M |
| Long Term Debt | $201.92M | $197.55M | $211.14M | $182.34M | $180.10M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $38.87M | $- | $- | $- | $- |
| Total Non-Current Liabilities | $240.79M | $197.55M | $211.14M | $182.34M | $180.10M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $285.80M | $249.15M | $260.37M | $222.19M | $218.75M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $23.00K | $23.00K | $10.00K | $8.00K | $8.00K |
| Retained Earnings | $-1.27B | $-1.21B | $-1.03B | $-811.53M | $-577.53M |
| Accumulated Other Comprehensive Income Loss | $1.19M | $-350.00K | $-574.00K | $45.00K | $599.00K |
| Other Total Stockholders Equity | $1.30B | $1.28B | $1.04B | $932.94M | $897.61M |
| Total Stockholders Equity | $29.49M | $62.77M | $-1.03B | $-811.53M | $-577.53M |
| Total Equity | $29.49M | $62.77M | $-1.03B | $-811.53M | $-577.53M |
| Total Liabilities and Stockholders Equity | $315.29M | $311.92M | $-771.85M | $-589.34M | $-358.78M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $315.29M | $311.92M | $-771.85M | $-589.34M | $-358.78M |
| Total Investments | $248.44M | $264.32M | $143.71M | $141.81M | $26.57M |
| Total Debt | $202.88M | $212.46M | $225.74M | $185.24M | $183.73M |
| Net Debt | $156.81M | $180.35M | $113.77M | $1.83M | $-302.32M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $46.07M | $28.46M | $86.88M | $38.86M | $32.11M | $82.61M | $37.00M | $65.24M | $111.97M | $153.48M | $94.32M | $138.91M | $183.40M | $213.47M | $342.45M | $439.66M | $486.06M | $461.96M | $486.06M | $111.35M |
| Short Term Investments | $248.44M | $298.57M | $267.61M | $205.53M | $264.32M | $246.28M | $125.12M | $136.61M | $143.71M | $150.91M | $127.84M | $132.72M | $141.81M | $152.55M | $63.47M | $13.64M | $26.57M | $93.42M | $114.30M | $234.81M |
| Cash and Short Term Investments | $294.52M | $327.03M | $354.49M | $244.39M | $296.43M | $328.89M | $162.13M | $201.86M | $255.68M | $304.38M | $222.16M | $271.62M | $325.22M | $366.02M | $405.92M | $453.30M | $512.63M | $555.38M | $600.36M | $346.17M |
| Net Receivables | $5.34M | $6.59M | $3.63M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $-100.00K | $- | $- | $-100.00K | $-200.00K | $-136.00K | $-136.00K | $-136.00K | $466.00K | $365.00K | $- | $- | $- | $- |
| Other Current Assets | $10.03M | $10.65M | $12.79M | $10.88M | $10.09M | $12.60M | $11.25M | $8.56M | $12.40M | $7.55M | $10.32M | $9.15M | $6.56M | $7.97M | $11.07M | $12.55M | $9.69M | $10.33M | $7.44M | $7.97M |
| Total Current Assets | $309.89M | $344.27M | $370.90M | $255.27M | $306.52M | $341.49M | $173.38M | $210.41M | $261.88M | $312.03M | $232.68M | $280.77M | $331.78M | $373.99M | $416.99M | $465.85M | $522.32M | $555.38M | $608.40M | $355.44M |
| Property Plant Equipment Net | $5.12M | $6.33M | $2.49M | $3.48M | $4.78M | $5.79M | $7.60M | $8.75M | $9.89M | $10.88M | $11.91M | $12.89M | $10.80M | $11.93M | $14.45M | $15.61M | $16.08M | $17.11M | $16.05M | $15.41M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $26.57M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $283.00K | $283.00K | $59.00K | $613.00K | $618.00K | $649.00K | $770.00K | $743.00K | $680.00K | $629.00K | $1.25M | $1.02M | $1.08M | $1.11M | $1.07M | $1.01M | $-25.55M | $11.69M | $627.00K | $634.00K |
| Total Non-Current Assets | $5.40M | $6.61M | $2.54M | $4.09M | $5.40M | $6.43M | $8.37M | $9.49M | $10.57M | $11.51M | $13.16M | $13.90M | $11.88M | $13.05M | $15.52M | $16.62M | $17.11M | $28.80M | $16.68M | $16.04M |
| Other Assets | $- | $- | $1 | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $315.29M | $350.88M | $373.45M | $259.36M | $311.92M | $347.93M | $181.75M | $219.91M | $272.45M | $323.54M | $245.84M | $294.68M | $343.66M | $387.04M | $432.51M | $482.47M | $539.43M | $584.18M | $625.08M | $371.48M |
| Account Payables | $2.32M | $3.06M | $1.00M | $2.66M | $5.53M | $1.25M | $2.21M | $2.73M | $1.46M | $363.00K | $3.91M | $592.00K | $3.24M | $1.19M | $895.00K | $1.07M | $7.51M | $865.00K | $222.00K | $2.60M |
| Short Term Debt | $961.00K | $1.75M | $1.83M | $12.23M | $14.91M | $14.83M | $14.75M | $14.67M | $14.60M | $2.91M | $2.83M | $2.76M | $2.90M | $3.03M | $3.40M | $3.52M | $3.63M | $3.55M | $3.25M | $2.42M |
| Tax Payables | $- | $1.10M | $4.43M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $17.05M | $- | $17.01M | $- | $- | $-3.22M | $-3.14M | $- | $- | $- | $- | $- | $-2.90M | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $24.68M | $45.18M | $20.91M | $20.93M | $31.16M | $26.23M | $23.18M | $23.17M | $33.17M | $49.38M | $37.67M | $31.21M | $33.71M | $31.68M | $25.68M | $24.85M | $27.51M | $28.19M | $24.08M | $23.34M |
| Total Current Liabilities | $45.01M | $51.09M | $45.19M | $35.82M | $51.60M | $42.32M | $40.14M | $40.57M | $49.23M | $52.65M | $44.41M | $34.57M | $39.86M | $35.90M | $29.98M | $29.44M | $38.65M | $32.61M | $27.54M | $28.36M |
| Long Term Debt | $201.92M | $201.88M | $197.05M | $196.82M | $197.55M | $200.99M | $204.41M | $207.79M | $211.14M | $214.54M | $217.90M | $229.95M | $182.34M | $181.33M | $181.84M | $180.94M | $180.10M | $179.47M | $177.21M | $36.65M |
| Deferred Revenue Non-Current | $38.87M | $43.78M | $49.68M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $-49.68M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $240.79M | $245.66M | $246.73M | $196.82M | $197.55M | $200.99M | $204.41M | $207.79M | $211.14M | $214.54M | $217.90M | $229.95M | $182.34M | $181.33M | $181.84M | $180.94M | $180.10M | $179.47M | $177.21M | $36.65M |
| Other Liabilities | $- | $- | $1 | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $885.03M | $- | $- |
| Total Liabilities | $285.80M | $296.74M | $291.92M | $232.64M | $249.15M | $243.31M | $244.55M | $248.36M | $260.37M | $267.19M | $262.31M | $264.52M | $222.19M | $217.23M | $211.82M | $210.38M | $218.75M | $1.10B | $204.75M | $65.02M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $23.00K | $23.00K | $23.00K | $23.00K | $23.00K | $23.00K | $10.00K | $10.00K | $10.00K | $10.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $7.00K |
| Retained Earnings | $-1.27B | $-1.24B | $-1.20B | $-1.25B | $-1.21B | $-1.16B | $-1.12B | $-1.08B | $-1.03B | $-976.46M | $-917.10M | $-860.63M | $-811.53M | $-755.25M | $-695.00M | $-635.17M | $-577.53M | $-512.93M | $-455.11M | $-388.24M |
| Accumulated Other Comprehensive Income Loss | $1.19M | $-2.23M | $-518.00K | $-628.00K | $-350.00K | $-618.00K | $-481.00K | $-436.00K | $-574.00K | $-585.00K | $-514.00K | $-340.00K | $45.00K | $137.00K | $274.00K | $158.00K | $599.00K | $342.00K | $567.00K | $-505.00K |
| Other Total Stockholders Equity | $1.30B | $1.29B | $1.29B | $1.28B | $1.28B | $1.27B | $1.06B | $1.05B | $1.04B | $1.03B | $901.14M | $891.12M | $932.94M | $924.91M | $915.41M | $907.09M | $897.61M | $884.68M | $874.86M | $695.21M |
| Total Stockholders Equity | $29.49M | $54.14M | $81.53M | $26.72M | $62.77M | $104.62M | $-62.80M | $-28.46M | $-1.03B | $56.35M | $-16.46M | $30.16M | $121.46M | $169.81M | $220.69M | $272.08M | $320.68M | $-512.93M | $420.32M | $306.46M |
| Total Equity | $29.49M | $54.14M | $81.53M | $26.72M | $62.77M | $104.62M | $-62.80M | $-28.46M | $-1.03B | $56.35M | $-16.46M | $30.16M | $121.46M | $169.81M | $220.69M | $272.08M | $320.68M | $-512.93M | $420.32M | $306.46M |
| Total Liabilities and Stockholders Equity | $315.29M | $350.88M | $373.45M | $259.36M | $311.92M | $347.93M | $181.75M | $219.91M | $-771.85M | $323.54M | $245.84M | $294.68M | $343.66M | $387.04M | $432.51M | $482.47M | $539.43M | $584.18M | $625.08M | $371.48M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $315.29M | $350.88M | $373.45M | $259.36M | $311.92M | $347.93M | $181.75M | $219.91M | $-771.85M | $323.54M | $245.84M | $294.68M | $343.66M | $387.04M | $432.51M | $482.47M | $539.43M | $584.18M | $625.08M | $371.48M |
| Total Investments | $248.44M | $298.57M | $267.61M | $205.53M | $264.32M | $246.28M | $125.12M | $136.61M | $143.71M | $150.91M | $127.84M | $132.72M | $141.81M | $152.55M | $63.47M | $13.64M | $53.15M | $93.42M | $114.30M | $234.81M |
| Total Debt | $202.88M | $203.63M | $198.88M | $209.05M | $212.46M | $215.82M | $219.16M | $222.46M | $225.74M | $229.06M | $232.34M | $232.71M | $185.24M | $184.36M | $185.24M | $184.46M | $183.73M | $183.02M | $180.45M | $39.07M |
| Net Debt | $156.81M | $175.16M | $112.00M | $170.19M | $180.35M | $133.22M | $182.16M | $157.22M | $113.77M | $75.58M | $138.03M | $93.81M | $1.83M | $-29.11M | $-157.22M | $-255.20M | $-302.32M | $-278.94M | $-305.61M | $-72.28M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-56.53M | $-179.82M | $-229.38M | $-234.00M | $-243.36M |
| Depreciation and Amortization | $4.15M | $4.38M | $4.43M | $5.17M | $4.27M |
| Deferred Income Tax | $- | $- | $- | $359.00K | $-158.00K |
| Stock Based Compensation | $20.62M | $28.52M | $42.55M | $32.01M | $38.75M |
| Change in Working Capital | $39.46M | $-14.84M | $-4.46M | $774.00K | $-3.10M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-1.66M | $3.99M | $-1.81M | $-4.43M | $6.98M |
| Other Working Capital | $41.12M | $-18.83M | $-2.65M | $5.20M | $-10.08M |
| Other Non Cash Items | $-11.17M | $2.60M | $-177.00K | $6.81M | $27.24M |
| Net Cash Provided by Operating Activities | $-3.47M | $-159.16M | $-187.03M | $-188.89M | $-176.36M |
| Investments in Property Plant and Equipment | $- | $- | $-475.00K | $-1.62M | $-24.88M |
| Acquisitions Net | $- | $- | $-65.00K | $75.00K | $23.38M |
| Purchases of Investments | $-494.78M | $-441.67M | $-238.06M | $-152.03M | $-108.97M |
| Sales Maturities of Investments | $523.80M | $330.70M | $237.50M | $36.23M | $349.19M |
| Other Investing Activities | $- | $- | $65.00K | $-75.00K | $-23.38M |
| Net Cash Used for Investing Activities | $29.02M | $-110.97M | $-1.03M | $-117.43M | $215.34M |
| Debt Repayment | $-12.58M | $-11.61M | $-5.81M | $- | $193.60M |
| Common Stock Issued | $464.00K | $201.32M | $119.95M | $3.33M | $117.11M |
| Common Stock Repurchased | $629.00K | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.09M | $888.00K | $2.95M | $3.33M | $1.83M |
| Net Cash Used Provided by Financing Activities | $-11.49M | $190.15M | $117.09M | $3.33M | $312.54M |
| Effect of Forex Changes on Cash | $-102.00K | $110.00K | $-517.00K | $-165.00K | $9.00K |
| Net Change in Cash | $13.96M | $-79.86M | $-71.49M | $-303.15M | $351.53M |
| Cash at End of Period | $46.07M | $32.11M | $111.97M | $183.47M | $486.62M |
| Cash at Beginning of Period | $32.11M | $111.97M | $183.47M | $486.62M | $135.09M |
| Operating Cash Flow | $-3.47M | $-159.16M | $-187.03M | $-188.89M | $-176.36M |
| Capital Expenditure | $- | $- | $-475.00K | $-1.62M | $-24.88M |
| Free Cash Flow | $-3.47M | $-159.16M | $-187.51M | $-190.51M | $-201.24M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-33.03M | $-30.80M | $49.23M | $-41.93M | $-48.15M | $-40.01M | $-42.50M | $-49.16M | $-55.76M | $-59.36M | $-56.47M | $-57.78M | $-56.28M | $-60.25M | $-59.83M | $-57.64M | $-64.60M | $-57.81M | $-66.87M | $-54.07M |
| Depreciation and Amortization | $1.07M | $1.10M | $992.00K | $986.00K | $1.01M | $1.09M | $1.15M | $1.14M | $1.12M | $1.11M | $1.10M | $1.10M | $1.28M | $1.31M | $1.30M | $1.27M | $1.21M | $1.18M | $987.00K | $895.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-3.78M | $-2.11M | $-1.50M | $- | $- | $- | $- | $- | $89.00K | $155.00K | $49.00K | $66.00K | $74.00K | $54.00K | $-182.00K | $-104.00K |
| Stock Based Compensation | $4.96M | $4.84M | $5.00M | $5.81M | $6.03M | $6.16M | $8.20M | $8.13M | $11.45M | $10.12M | $10.00M | $10.98M | $7.66M | $7.59M | $8.05M | $8.71M | $12.68M | $8.92M | $8.90M | $8.24M |
| Change in Working Capital | $-5.55M | $-49.06M | $63.80M | $-14.73M | $960.00K | $77.00K | $-3.95M | $-11.93M | $-3.68M | $11.22M | $-3.79M | $-8.21M | $4.98M | $7.44M | $1.29M | $-12.94M | $7.04M | $982.00K | $-968.00K | $-10.15M |
| Accounts Receivables | $1.25M | $3.63M | $-3.63M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $3.08M | $-295.00K | $-1.52M | $-2.92M | $4.26M | $-988.00K | $-507.00K | $1.22M | $285.00K | $-3.30M | $3.71M | $-2.51M | $2.38M | $-177.00K | $-66.00K | $-6.57M | $6.97M | $737.00K | $-2.34M | $1.61M |
| Other Working Capital | $-9.88M | $-52.40M | $68.94M | $-11.81M | $-3.30M | $1.06M | $-3.44M | $-13.15M | $-3.96M | $14.53M | $-7.50M | $-5.71M | $2.60M | $7.62M | $1.35M | $-6.37M | $67.00K | $245.00K | $1.37M | $-11.76M |
| Other Non Cash Items | $-2.94M | $41.89M | $5.83M | $8.27M | $10.51M | $293.00K | $353.00K | $-1.16M | $-859.00K | $-89.00K | $334.00K | $437.00K | $1.76M | $1.71M | $1.69M | $1.64M | $6.86M | $1.75M | $15.73M | $2.89M |
| Net Cash Provided by Operating Activities | $-35.48M | $-32.03M | $116.35M | $-52.30M | $-33.42M | $-34.49M | $-38.25M | $-52.99M | $-47.73M | $-37.00M | $-48.82M | $-53.48M | $-40.51M | $-42.03M | $-47.45M | $-58.90M | $-36.74M | $-44.93M | $-42.40M | $-52.30M |
| Investments in Property Plant and Equipment | $- | $116.35M | $-116.35M | $- | $60.00K | $-30.00K | $-15.00K | $-15.00K | $-117.00K | $-46.00K | $-135.00K | $-177.00K | $-98.00K | $-538.00K | $-153.00K | $-832.00K | $-5.55M | $-574.00K | $-15.44M | $-3.32M |
| Acquisitions Net | $- | $- | $- | $- | $-30.00K | $30.00K | $15.00K | $- | $-15.00K | $-50.00K | $-15.00K | $-20.00K | $-75.00K | $15.00K | $-15.00K | $-30.00K | $-23.38M | $275.00K | $15.00M | $-2.81M |
| Purchases of Investments | $-83.68M | $-131.35M | $-193.61M | $-86.13M | $-120.27M | $-188.09M | $-56.45M | $-76.86M | $-77.42M | $-88.05M | $-35.19M | $-37.40M | $-8.13M | $-93.97M | $-49.92M | $30.00K | $1.00K | $-35.19M | $1.00K | $-73.78M |
| Sales Maturities of Investments | $136.90M | $104.60M | $134.50M | $147.80M | $105.90M | $69.80M | $69.40M | $85.60M | $86.00M | $65.50M | $40.00M | $46.00M | $18.68M | $4.75M | $- | $12.80M | $66.65M | $55.73M | $121.69M | $105.13M |
| Other Investing Activities | $- | $-116.35M | $-59.11M | $61.67M | $-14.37K | $30.00K | $-15.00K | $- | $15.00K | $50.00K | $15.00K | $20.00K | $75.00K | $-15.00K | $-49.94M | $12.77M | $23.38M | $-275.00K | $-15.00M | $2.81M |
| Net Cash Used for Investing Activities | $53.22M | $-26.75M | $-59.11M | $61.67M | $-14.37M | $-118.26M | $12.94M | $8.72M | $8.46M | $-22.60M | $4.68M | $8.42M | $10.44M | $-89.76M | $-50.08M | $11.97M | $61.10M | $19.96M | $106.25M | $28.04M |
| Debt Repayment | $- | $- | $-9.68M | $-2.90M | $-2.90M | $-2.90M | $-2.90M | $-2.90M | $-2.90M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-812.00K | $464.00K | $348.00K | $-444.00K | $201.40M | $- | $- | $18.00K | $119.93M | $21.00K | $721.00K | $2.01M | $1.91M | $271.00K | $774.00K | $- | $16.00K | $116.54M | $556.00K |
| Common Stock Repurchased | $- | $281.00K | $- | $348.00K | $77.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $281.00K | $464.00K | $348.00K | $- | $201.40M | $- | $367.00K | $12.00K | $119.22M | $21.00K | $721.00K | $371.00K | $1.91M | $271.00K | $774.00K | $249.00K | $875.00K | $194.29M | $15.00K |
| Net Cash Used Provided by Financing Activities | $- | $281.00K | $-9.21M | $-2.56M | $-2.90M | $198.50M | $-2.90M | $-2.54M | $-2.87M | $119.22M | $21.00K | $721.00K | $371.00K | $1.91M | $271.00K | $774.00K | $249.00K | $891.00K | $310.83M | $571.00K |
| Effect of Forex Changes on Cash | $-125.00K | $93.00K | $-8.00K | $-62.00K | $193.00K | $-136.00K | $-19.00K | $72.00K | $635.00K | $-465.00K | $-533.00K | $-154.00K | $-376.00K | $403.00K | $50.00K | $-242.00K | $51.00K | $-26.00K | $34.00K | $-50.00K |
| Net Change in Cash | $17.61M | $-58.41M | $48.01M | $6.75M | $-50.50M | $45.60M | $-28.24M | $-46.73M | $-41.50M | $59.16M | $-44.66M | $-44.50M | $-30.07M | $-129.48M | $-97.20M | $-46.40M | $24.66M | $-24.11M | $374.71M | $-23.74M |
| Cash at End of Period | $46.07M | $28.46M | $86.88M | $38.86M | $32.11M | $82.61M | $37.00M | $65.24M | $111.97M | $153.48M | $94.32M | $138.97M | $183.47M | $213.54M | $343.02M | $440.22M | $486.62M | $461.96M | $486.06M | $111.35M |
| Cash at Beginning of Period | $28.46M | $86.88M | $38.86M | $32.11M | $82.61M | $37.00M | $65.24M | $111.97M | $153.48M | $94.32M | $138.97M | $183.47M | $213.54M | $343.02M | $440.22M | $486.62M | $461.96M | $486.06M | $111.35M | $135.09M |
| Operating Cash Flow | $-35.48M | $-32.03M | $116.35M | $-52.30M | $-33.42M | $-34.49M | $-38.25M | $-52.99M | $-47.73M | $-37.00M | $-48.82M | $-53.48M | $-40.51M | $-42.03M | $-47.45M | $-58.90M | $-36.74M | $-44.93M | $-42.40M | $-52.30M |
| Capital Expenditure | $- | $116.35M | $-116.35M | $- | $60.00K | $-30.00K | $-15.00K | $-15.00K | $-117.00K | $-46.00K | $-135.00K | $-177.00K | $-98.00K | $-538.00K | $-153.00K | $-832.00K | $-5.55M | $-574.00K | $-15.44M | $-3.32M |
| Free Cash Flow | $-35.48M | $-32.03M | $- | $-52.30M | $-33.36M | $-34.52M | $-38.27M | $-53.00M | $-47.85M | $-37.04M | $-48.96M | $-53.66M | $-40.61M | $-42.57M | $-47.60M | $-59.73M | $-42.29M | $-45.50M | $-57.84M | $-55.61M |
Gossamer Bio Dividends
Explore Gossamer Bio's dividend history, including dividend yield, payout ratio, and historical payments.
Gossamer Bio News
Read the latest news about Gossamer Bio, including recent articles, headlines, and updates.
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. “As we close the book on 2024 and embrace the promise of 2.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective March 5, 2025, to five non-executive employees of non-qualified stock opti.
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS's pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM.
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented one oral presentation and three posters related to seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February.
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced one oral and three poster presentations related to seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress taking place January 29th through Febru.
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025.
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California. Details.
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
SAN DIEGO, Calif. & PARMA, Italy--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (“Gossamer”) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A (“Chiesi Group”), an international, research-focused biopharmaceutical group, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib. This glob.
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine journal. The paper, titled "Seralutinib in Adults with Pulmonary Arterial Hypertensio.
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors. Dr. Nathan is Medical Director of Inova's Advanced Lung Disease Program and Lung Transpla.
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update. “We were thrilled to enroll the first patient in the registrational PROSERA Study last year, and we are pleased with the pace of site activati.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for GOSS.